We report two cases of successful intra-lesional injections of sodium thiosulfate (STS). Results: Case 1: A 44-years old woman, with history of dermatomyositis developed in 2009 several TC involving the extensor surfaces of the right elbow and forearm, the two ischiatic regions, fingers and lumbar back. As TC kept growing despite successive treatments, including intravenous STS, we proposed weekly intra-lesional injections of 10% STS in the elbow's lesion. The injected volume varied from 10 to 30 mL at each session. Fourrier transform infrared spectroscopy (FTIR) of the aspirations confirmed that TC was composed of carbonated-apatite crystals. After 6-month treatment, we observed clinical and radiological regression of elbow TC whereas bottom TC and finger calcifications were unchanged (Fig 1) . No side effect was observed except a subcutaneous infection occurring after an injection during the fifth month. This infection resolved with anti-staphycoccal antibiotics. Calcium, bicarbonate and chlorus serum levels, anion gap and eGFR remained unchanged during STS treatment. Case 2: A 42-year old male presented with a prolonged history of hyperphosphatemic familial TC, confirmed by genetic analysis revealing homozygous mutations in the gene encoding the fibroblast growth factor 23. The extraosseous calcifications comprised a plain lesion on the right side of the left tibia and a massive heterogeneous lesion in the right buttock, making it the sitting position impossible. Treatment with maximal dose of phosphate binders, diet prescription and an attempt to surgically remove of the buttock's lesion were unsuccessful. Topical application of STS led to a near complete disappearance of the tibial lesion but was inefficient to treat the TC at the buttock. Considering the potential efficacy of STS in this patient, local injections of 25% STS (12 mL every week) were performed. The calcified material aspiration's analysis confirmed that TC was composed of carbonated-apatite crystals. Calcium and bicarbonate serum levels, anion gap and eGFR remained unchanged. After a 12-month treatment of STS injections, the lesion had significantly regressed (Fig 2) , allowing the patient to sit again with no pain.
Objectives: To evaluate the prevalence of ultrasonographic gout specific signs of hand and fingers joints. Methods: This is a cross-sectional study which includes 15 patients with chronic gout, defined according to the American College of Rheumatology criteria (ACR 1977) . Ultrasound (US) examination was performed using a high-frequency linear probe (Toshiba Xario ® , frequency (8-14 MHz)) in B mode. 540 articular sites were studied at their dorsal surface. The ultrasound has objectified the presence of two signs: hyperechoic band over the superficial margin of the articular cartilage described as a double contour (DC) and the tophaceous deposits at the joint cavity.
Results:
The mean age at onset was 54.7±12,6 years, and the median diagnosis duration was 0 (0.3) years). The results of the US examination are summarized in Table 1 . Conclusions: This study showed a predilection for the gout specific ultrasound signs (DC and tophaceous deposits) of the wrist and MCP joints. The contribution of musculoskeletal ultrasound seems to be very interesting to objectify the presence of gout specific signs in the hand and fingers joints. Objectives: To evaluate the prevalence of ultrasonographic gout specific signs of foot joints. Methods: This is a cross-sectional study which includes 15 patients with chronic gout, defined according to the American College of Rheumatology criteria (ACR 1977) . Ultrasound (US) examination was performed using a high-frequency linear probe (Toshiba Xario ® , frequency (8-14 MHz)) in B mode. 330 articular sites were studied at their dorsal surface. The ultrasound has objectified the presence of two signs: hyperechoic band over the superficial margin of the articular cartilage described as a double contour (DC) and tophaceous deposits at the joint cavity.
The mean age at onset was 54.7±12,6 years, and the median diagnosis duration was 0 (0.3) years). The results of the US examination are summarized in Table 1 . Conclusions: This study showed a predilection for the gout specific ultrasound signs (DC and tophaceous deposits) in the tarsometatarsal and metatarsophalangeal joints, especially in the first MTP. The contribution of musculoskeletal ultrasound seems to be very interesting to objectify the presence of gout specific signs of the foot joints. Background: Verinurad (RDEA3170) is a selective uric acid reabsorption inhibitor in clinical development for the treatment of gout and asymptomatic hyperuricemia. Objectives: The aim of this study was to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of verinurad following single and multiple doses in healthy adult males. Methods: This was a Phase 1, randomized, double-blind, placebo-controlled, single-and multiple-ascending dose study. Panels of 8 male subjects (6 active, 2 placebo) received a single oral dose of verinurad or placebo in either a fasted (2 mg, 5 mg, 20 mg, 40 mg) or fed (5 mg, 20 mg) state and panels of 12 male subjects (9 active, 3 placebo) received ascending doses of once-daily verinurad (1 mg, 5 mg, and 10 mg) or placebo in a fasted state for up to 10 days. Verinurad was administered as an oral solution for 1 and 2 mg doses and in tablet form for doses >2 mg. Serial plasma/serum and urine samples were assayed for verinurad and uric acid at predetermined time points. Safety was assessed by adverse event (AE) reports, laboratory tests, vital signs, and electrocardiograms (ECGs). Results: A total of 81 adult males aged 18-54 years enrolled and completed the study. Following single oral doses of verinurad, absorption was rapid and exposure (maximum plasma concentration [C max ] and area under the plasma concentrationtime curve [AUC]) increased in a dose-proportional manner up to the maximum dose tested; C max was achieved at 0.5-0.75 hours post-dose in the fasted state, and was slightly delayed to 1.25 hours post-dose in the fed state. Food appeared to decrease AUC by about 23% and C max by about 50%. Following multiple daily doses, there was modest accumulation of verinurad. Urinary excretion of verinurad accounted for approximately 2% of the administered dose, suggesting that renal excretion is a minor elimination pathway for unchanged verinurad. Reductions in serum uric acid (sUA) correlated with dose. Under fasted conditions, single-dose administration of verinurad 2, 5, 20, or 40 mg reduced sUA levels by 16%, 24%, 48%, and 62%, respectively. Following multiple once-daily dosing for 10 days, verinurad reduced sUA levels by 22%, 44%, and 61% for the 1, 5, and 10 mg doses, respectively. A persistent pharmacologic effect (>15% fractional excretion of uric acid relative to baseline) was evident for at least 24 hours after dosing for verinurad doses of 2 mg or above. Verinurad was well tolerated at all doses. No serious AEs, severe AEs, discontinuations due to AEs or clinically significant laboratory or ECG abnormalities were reported. Conclusions: Single and multiple doses of verinurad were well tolerated, absorption was rapid and exposure was dose-proportional. Verinurad increased urinary uric acid elimination and resulted in sustained reductions in sUA. These data support further clinical evaluation of once-daily verinurad as a treatment for gout. Acknowledgements: The authors thank Caroline Lee of Ardea Biosciences, Inc. for critical review of the abstract. Background: Chronic gout is a significant clinical problem in Asia, including Japan, where many patients remain suboptimally treated with currently available therapies. Verinurad (RDEA3170) is a selective uric acid reabsorption inhibitor in clinical development for the treatment of gout and asymptomatic hyperuricemia. Objectives: The aim of this study was to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of verinurad in healthy Japanese and nonAsian adult male subjects. Methods: This was a Phase 1, randomized, single-blind, placebo-controlled study (NCT01872832). Panels of 8 Japanese male subjects were randomized in a 3:1 ratio to receive a modified-release formulation of oral verinurad (2.5 mg, 5 mg, 10 mg, 15 mg) or placebo administered as a single dose in a fasted state and as multiple once-daily doses in a fed state for 7 days. A panel of 8 non-Asian male subjects received single and multiple doses of oral verinurad (10 mg) or placebo. Serial plasma/serum and urine samples were assayed for verinurad and uric acid at predetermined time points. Safety was assessed by adverse event (AE) reports, laboratory tests, vital signs, and electrocardiograms (ECGs). Results: Of 48 randomized subjects, 46 (Japanese: 39, non-Asian: 7) completed the study. Treatment groups were generally well balanced; however, mean body weight and body mass index were approximately 14% and 7% lower, respectively, in Japanese than non-Asian subjects. Following single-or multiple-oral doses of verinurad in Japanese subjects, exposure (maximum plasma concentration [C max ] and area under the plasma concentration-time curve [AUC]) increased in a near dose-proportional manner under fasted or fed conditions. The time to C max (T max ) was approximately 1.25-2.0 hours post-dose under fasted conditions. A moderate-fat meal delayed T max up to 5 hours post-dose and increased plasma verinurad exposures up to 109%. Following once-daily multiple doses, there was modest accumulation of verinurad. C max and AUC were 38% and 23% higher, respectively, in Japanese versus non-Asian subjects, largely due to the difference in body weight. Mean reductions in serum uric acid following once-daily multiple dosing of verinurad 10 mg were 62% and 58% at maximum reduction and 46% and 44% at 24 hours post-dose in Japanese and non-Asian subjects, respectively. Verinurad was well tolerated at all doses. One Japanese subject discontinued verinurad due to an AE of urticaria that resolved after 11 days. No serious AEs, Grade 3 or 4 AEs, or clinically significant laboratory or ECG abnormalities were noted. Conclusions: Verinurad significantly lowered serum uric acid and was well tolerated in both healthy Japanese and non-Asian males, despite small differences in plasma pharmacokinetics. These data support further evaluation of once-daily verinurad as a treatment for hyperuricemia with or without gout in the Japanese population.
